From membrane differential filtration to lipidfiltration: Technological progress in low-density lipoprotein apheresis

Therapeutic Apheresis

Volumn 7, Issue 3, 2003, Pages 350-358

  Klingel, Reinhard ^a   Fassbender, Thurid ^a   Fassbender, Cordula ^a   Göhlen, Britta ^a  

^a Apheresis Research Institute   (Germany)

Author keywords

Coronary artery disease; Double filtration plasmapheresis; Fibrinogen; Hemorheology; Hypercholesterolemia; LDL apheresis; Lipid apheresis; Lipidfiltration; Low density lipoprotein cholesterol; Membrane differential filtration

Indexed keywords

FIBRINOGEN; LOW DENSITY LIPOPROTEIN;

ARTICLE; BLOOD FILTRATION; BLOOD RHEOLOGY; CHOLESTEROL BLOOD LEVEL; EXTRACORPOREAL CIRCULATION; FAMILIAL HYPERCHOLESTEROLEMIA; LONG TERM CARE; MEMBRANE FILTER; METHODOLOGY; PLASMAPHERESIS; PRIORITY JOURNAL; TREATMENT INDICATION;

ADULT; AGED; BLOOD COMPONENT REMOVAL; CHOLESTEROL, LDL; CORONARY ARTERIOSCLEROSIS; FEMALE; FILTRATION; FOLLOW-UP STUDIES; HUMANS; HYPERCHOLESTEROLEMIA; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PLASMAPHERESIS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0038148618     PISSN: 10916660     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1526-0968.2003.00062.x     Document Type: Article

References (67)

1. Thompson GR, Maher VMG, Matthews S et al. Familial hypercholesterolaemia regression study: a randomised trial of low-density-lipoprotein apheresis. Lancet 1995;345:811-16.
2. Kroon AA, Aengevaeren WR, van der Werf T et al. LDL apheresis atherosclerosis regression study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation 1996;93:1826-35.
3. Mabuchi H, Koizumi J, Shimizu M et al. Long-term Efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group. Am J Cardiol 1998;82:1489-95.
4. Schuff-Werner P, Gohlke H, Bartmann U, Baggio G, Corti MC, Dinsenbacher A. The HELP-LDL-apheresis multicentre study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. II. Final evaluation of the effect of regular treatment on LDL-cholesterol plasma concentration and the course of coronary heart disease. Eur J Clin Invest 1994;24:724-32.
5. Bosch T, Lennertz A, Kordes B, Samtleben W. Low densitiy lipoprotein hemoperfusion by direct adsorption of lipoproteins from whole blood (DALI Apheresis): clinical experience from a single center. Ther Apher 1999;3:209-13.
6. Drager LJ, Julius U, Kraenzle K, et al. DALI: the first human whole-blood low-density lipoprotein and lipoprotein (a) apheresis system in clinical use: procedure and clinical results. Eur J Clin Invest 1998, 1992;28:994-1002.
7. Godehardt E, Messner H et al. Extracorporeal LDL cholesterol elimination by membrane differential filtration. A retrospective analysis of 1702 treatments. In: Gotto AM Jr, Mancini M, Richter WO Schwandt P, eds. Treatment of Severe Dyslipoproteinemia in the Prevention of Coronary Heart Disease, 4th International Symp, Munich. Basel: Karger, 1993;208-12.
8. Jansen M, Banyai S, Schmaldienst S et al. Direct adsorption of lipoproteins (DALI) from whole blood: First long-term clinical experience with a new LDL apheresis system for the treatment of familial hypercholesterolemia. Wien Klin Wochenschr 2000;112/2:61-9.
9. Julius U, Metzler W, Pietzsch J, Fassbender T, Klingel R. Intraindividual comparison of two extracorporeal LDL apheresis methods: Lipidfiltration and HELP. Int J Artif Organs 2002;25:1180-8.
10. Schmaldienst S, Banyai S, Stulnig TM et al. Prospective randomised cross-over comparison of three LDL apheresis systems in statin pretreated patients with familial hypercholesterolaemia. Atherosclerosis 2000;151:493-9.
11. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
12. Schettler V, Wieland E, Armstrong VW et al. First steps toward the establishment of a German low-density lipoprotein-apheresis registry: recommendations for the indication and for quality management. Ther Apher 2002;6:381-3.
13. Jaeger BR, Goehring P, Schirmer J et al. Consistent lowering of clotting factors for the treatment of acute cardiovascular syndromes and hypercoagulability: a different pathophysiological approach. Ther Apher 2001;5:252-9.
14. Julius U, Siegert G, Gromeier S. Intraindividual comparison of the impact of two selective apheresis methods (DALI and HELP) on the coagulation system. Int J Artif Organs 2000;23:199-206.
15. Agishi T, Kaneko J, Hasuo Y et al. Double filtration plasmapheresis with no or minimal amount of blood derivative for substitution. In: Sieberth HG, ed. Plasma Exchange, Plasmapheresis, Plasmaseparation. Stuttgart: Schattauer Verlag, 1980;53-7.
16. Nosé Y, Malchesky PS, Asanuma Y et al. Plasma filtration detoxification on hepatic patients: its optimal operating conditions. In: Gurland HJ, Heinze V, Lee HA, eds. Therapeutic Plasma Exchange 4. Basel: Springer-Verlag, 1981;125-35.
17. Matsuda Y, Malchesky PS, Nosé Y. Low-density lipoprotein removal methods by membranes and future perspectives. Artif Organs 1996;20:346-55.
18. Matsuda Y, Sueoka A, Nosé Y. An effective LDL removal filter for the treatment of hyperlipidemia. Artif Organs 1995;19:129-34.
19. Donner MG, Richter O, Schwandt P. Plasma lipoproteins under LDL apheresis by cascade filtration. Atherosclerosis 1996; 66th Congress of the European Atherosclerosis Society: 209.
20. Suzuki M, Yamane S, Matsugane T, Nobuto T, Azuma N et al. Evaluation of double filtrationplasmapheresis, thermofiltration, and low-density lipoprotein adsorptive methods by crossover test in the treatment of familial hypercholesterolemia patients, Artif Organs 1996;20:296-302.
21. Baeyer H, Schartl M, Schwerdtfeger R et al. Results of long-term treatment of severe familial hypercholesrolemia with differential filtration LDL apheresis. In: Gotto AM, Mancini M, Richter WO, Schwandt P, eds. Treatment of Severe Dyslipoproteinemia in the Prevention of Coronary Heart Disease 4, 4th International Symposium. Munich, 1992, Basel: Karger, 1993;208-12.
22. Franceschini G, Busnach G, Vaccarino V, Calabresi L, Gianfranceschi G, Sirtori CR. Apheretic treatment of severe familial hypercholesterolemia: comparison of dextran sulfate cellulose and double membrane filtration methods for low density lipoprotein removal. Atherosclerosis 1988;73:197-202.
23. Geiss HC, Parhofer KG, Donner MG, Schwandt P. Low density lipoprotein apheresis by membrane differential filtration (cascade filtration). Ther Apher 1999;3:199-202.
24. Parhofer KG, Geiss HC, Schwandt P. Efficacy of different low-density lipoprotein apheresis methods. Ther Apher 2000;4:382-5.
25. Seidel D, Armstrong VW, Schuff-Werner P, The HELP-LDL-apheresis multicentre study, an angiographically assessed trial on the role of LDL-apheresis in the secondary prevention of coronary heart disease. I. Evaluation of safety and cholesterol-lowering effects during the first 12 months. HELP Study Group. Eur J Clin Invest 1991;21:375-83.
26. Krebs A, Zellner D, Braun N et al. Multicentre comparison of 5 methods for long-term lipid apheresis between years 1986-2001 in 20 Patients. Kidney Blood Press Res 2001;24:313-14.
27. Meier P, Blanc E. Long-term efficacy of lipoprotein apheresis in homozygous familial hypercholesterolaemia. Neprhol Dial Transplant 2000;15:738-9.
28. Yamane S, Matsugane T, Motohashi K et al. Double filtration plasmapheresis maintains normal adhesion molecule levels. Ther Apher 1998;2:224-7.
29. Nitschke M, Fink K, Pawlow-Handt S, Leeker A, Rob PM, Steinhoff J. Acute renal failure in IgM plasmocytoma with hyperviscosity syndrome. Dtsch Med Wochenschr 1997;122:1213-16.
30. Poredos P, Zizek B. Plasma viscosity increase with progression of peripheral arterial atherosclerotic disease. Angiology 1996;47:253-9.
31. Otto C, Ritter MM, Richter WO, Minkenberg R, Schwandt P. Hemorrheologic abnormalities in defined primary dyslipoproteinemias with both high and low atherosclerotic risks. Metabolism 2001;50:166-70.
32. Koenig W, Ernst E. The possible role of hemorheology in atherogenesis. Atherosclerosis 1992;94:93-107.
33. Jung F, Pindur G, Kiesewetter H. Plasma viscosity dependence on proteins and lipoproteins. Clin Hemorheol 1992;12:557-71.
34. Tamai O, Matsuoka H, Itabe H, Wada Y, Kohno K, Imaizumi T. Single LDL-apheresis improves endothelium-dependent vasodilation in hypercholesterolemic humans. Circulation 1997;95:76-82.
35. Jaeger BR. Evidence for maximal treatment of atherosclerosis: drastic reduction of cholesterol and fibrinogen restores vascular homeostatsis. Ther Apher 2001;5:207-11.
36. Messner H, Godehardt E, Köbberling J et al. Membrane differential filtration in extracorporeal LDL-cholesterol elimination. In: Gotto AM, Mancini M, Richter WO, Schwandt P, eds. Treatment of Severe Dyslipoproteinemia in the Prevention of Coronary Heart Disease 4, 4th International Symp, Munich 1992. Basel: Karger, 1993;204-7.
37. Tschöpe W, Wallstab UH et al. Cascade Filtration for LDL Apheresis. Increase of Selectivity. In: Gotto AM Jr, Mancini M Richter WO Schwandt P, eds. Treatment of Severe Dyslipoproteinemia in the Prevention of Coronary Heart Disease. Basel: Karger, 1993;213-18.
38. Koenig W, Sund M, Ernst E. Association between rheology and components of lipoproteins in human blood. Results from the MONICA Project. Circulation 1992;85:2197-204.
39. Schamberger BM, Geiss HC, Ritter MM, Schwandt P, Parhofer KG. Influence of LDL apheresis on LDL subtypes in patients with coronary heart disease and severe hyperlipoproteinemia. J Lipid Res 2000;41:727-33.
40. Donner MG, Parhofer KG, Richter WO, Schwandt P. Low-density lipoprotein (LDL) oxidizability before and after LDL apheresis. Metabolism 1999;48:881-6.
41. Lepage S, Nigon F, Bonnefont-Rousselot D et al. Oxidizability of atherogenic low-density lipoprotein subspecies in severe familial hypercholesterolemia: impact of long-term low-density lipoprotein apheresis. J Cardiovasc Pharmacol Ther 2000;5:87-103.
42. Pietzsch J, Lattke P, Julius U. Oxidation of apolipoprotein B-100 in circulating LDL is related to LDL residence time. In vivo insights from stable-isotope studies. Arterioscier Thromb Vasc Biol 2000;20:E63-7.
43. Pietzsch J, Julius U. Different susceptibility to oxidation of proline and arginine residues of apolipoprotein B-100 among sucspecies of low density lipoproteins. FEBS Lett 2001;23:123-6.
44. Goldman L, Gordon DJ, Rifkind BM et al. Cost and health implications of cholesterol lowering. Circulation 1992;85:1960-8.
45. Schnell G. Kostenanalyse. In: Lauterbach KW, Schrappe M, eds. Gesundheitsökonomie, Qualitätsmanagement und Evidence-Based Medicine. Stuttgart: Schattauer, 2001;133-7.
46. Windler E. Gesundheitsökonomie der Behandlung von Fettstoffwechselstörungen. Herz 2000;25:476-86.
47. Kostner KM, Kostner GM. Lowering cholesterol 1998. Cholesterol synthesis inhibitors compared. Wien Klin Wochenschr 1998;110:625-30.
48. Brown G, Albers JJ, Fisher LD et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of Apolipoprotein B. N Eng J Med 1990;323:1289-98.
49. Goldberg AC. The impact of lipid lowering in coronary artery disease. Curr Opin Cardiol 1997;12:488-93.
50. Gotto AM, Grundy SM. Lowering LDL cholesterol: questions from recent meta-analyses and subset analyses of clinical trial data issues from the interdisciplinary council on reducing the risk for coronary heart disease. Ninth council meeting. Circulation 1999;99:E1-7.
51. Grundy SM. Prevention of coronary heart disease through cholesterol reduction. Am Fam Physician 1997;55:2250-8.
52. Hay JW, Winnie MY, Ashraf T. Pharmacoeconomics of lipid-lowering agents for primary and secondary prevention of coronary artery disease. Pharmacoeconomics 1999;15:47-74.
53. Richter WO, Donner MG, Höfling B, Schwandt P. Long-term effect of low-density lipoprotein apheresis on plasma lipoproteins and coronary heart disease in native vessels and coronary bypass in severe heterozygous familial hypercholesterolemia. Metabolism 1998;74:863-8.
54. Schaefer JR, Schweer H, Ikewaki K et al. Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease. Atherosclerosis 1999;144:177-84.
55. Smith SC. Review of recent clinical trials of lipid lowering in coronary artery disease. Am J Cardiol 1997;80:10H-13H.
56. Gagné C, Gaudet D, Bruckert E. Efficacy and safety of Ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 2002;105:2469-75.
57. Malchesky PS, Bambauer R, Horiuchi T, Kaplan A, Sakurada Y, Samuelsson G. Apheresis technologies: an international perspective. Artif Organs 1995;19:315-23.
58. Zarkowsky H. Managed care organizations' assessment of reimbursement for new technology, procedures, and drugs. Arch Pathol Laboratory Med 1999;123:677-9.
59. Hummelsheim T, Borberg H, Brunner R et al. Acute changes of haemorheological parameters by LDL apheresis: specific immunoadsorption versus cascade filtration. Infusionsther Transfusionsmed 1995;22:42-4. In: Gotto AM, Mancini M, Richter WO, Schwandt P, eds. Treatment of Severe Dyslipoproteinemia in the Prevention of Coronary Heart Disease 4, 4th International Sympopsium, Munich. Basel: Karger, 1993;194-203, 204-7.
60. Hummelsheim T, Borberg H, Brunner R et al. Acute changes of haemorheological parameters by LDL apheresis: specific immunoadsorption versus cascade filtration. Infusionsther Transfusionsmed 1995;22:42-4. In: Gotto AM, Mancini M, Richter WO, Schwandt P, eds. Treatment of Severe Dyslipoproteinemia in the Prevention of Coronary Heart Disease 4, 4th International Sympopsium, Munich. Basel: Karger, 1993;194-203, 204-7.
61. Eisenhauer T, Armstrong VW, Wieland H et al. Selective continuous elimination of low density lipoproteins (LDL) by heparin precipitation: first clinical application. Trans Am Soc Artif Intern Organs 1986;32:104-7.
62. Park JW, Merz M, Braun P. Effect of HELP-LDL-apheresis on outcomes in patients with advanced coronary atherosclerosis and severe hypercholesterolemia. Atherosclerosis 1998;139:401-9.
63. Richter WO, Donner MG, Schwandt P. Three low density lipoprotein apheresis techniques in treatment of patients with familial hypercholesterolemia: a long-term evaluation. Ther Apher 1999;3:203-8.
64. Schaumann D, Welch-Wichary M, Voss A, Schmidt H, Olbricht CJ. Prospective cross over comparison of three low-density lipoprotein (LDL)-apheresis methods in patients with familial hypercholesterolaemia. Eur J Clin Invest 1996;26:1033-8.
65. Bosch T, Schmidt B, Kleophas W, Otto V, Samtleben W. LDL hemoperfusion-a new procedure for LDL apheresis: biocompatibility results from a first pilot study in hypercholesterolemic atherosclerosis patients. Artif Organs 1997;21:1060-5.
66. Schulzeck P, Olbricht CJ, Koch KM. Long-term experience with extracorporeal low-density lipoprotein cholesterol removal by dextran sulfate cellulose adsorption. Clin Invest 1992;70:99-104.
67. Banyai S, Streicher J, Strobl W et al. Therapeutic efficiency of lipoprotein (a) reduction by low-density lipoprotein immunoapheresis. Metabolism 1998;47:1058-64.